<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859882</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol PERCAF 2018</org_study_id>
    <nct_id>NCT03859882</nct_id>
  </id_info>
  <brief_title>Protocol PERCAF 2018</brief_title>
  <acronym>PERCAF</acronym>
  <official_title>Polymorphisms and Efficiency of Caffeine on Performances During Total Sleep Deprivation un Healthy Subject. Multicentric, Versus Placebo, Randomised, Cross Over, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche Biomedicale des Armees</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherche Biomedicale des Armees</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicentric controlled study, we aims to evaluate effect of caffeine on mental
      performances during a sleep deprivation protocol. Genetic polymorphisms are considered as a
      covariable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coffee is the most consumed arousing substance in the world. Caffeine is used as a natural
      countermeasure to maintain the performance of sleep deprived subjects. However, the
      effectiveness of caffeine is characterized by a large individual variability, also observed
      on side effects. This variability could notably be related to polymorphisms of the adenosine
      receptor 2a gene (ADORA2A) and Tumor Necrosis Factor-alpha, a pro-inflammatory cytokine whose
      increase is observed during sleep deprivation.

      This study, under conditions of total sleep deprivation in the laboratory (40 hours of
      continuous awakening), examine the cross-influence of two polymorphisms (ADORA2A: rs5751876
      and TNF-alpha: rs1800629) on the sensitivity to caffeine and on the degradation of
      attentional performances. Physical performance, mental performance, immuno-inflammatory
      responses and the occurrence indesirable effects will be evaluate.

      This work aims to understand the mechanisms that contribute to increasing individual
      vulnerability and promoting protective countermeasures. The purpose of this project is to
      improve the recommendations concerning the daily use of caffeine and during periods of
      prolonged awakening, particularly in the military environment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2018</start_date>
  <completion_date type="Anticipated">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychomotor vigilance test Speed</measure>
    <time_frame>Change from Baseline Psychomotor vigilance test Speed at day 2 after 24 hours awaking</time_frame>
    <description>Speed at the Psychomotor vigilance test test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>Change from Baseline at day 2 after 25 hours awaking</time_frame>
    <description>Number of errors at executive performance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Force -velocity</measure>
    <time_frame>Change from Baseline at day 2 after 32 hours awaking</time_frame>
    <description>Power at the force-velocity test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Sleep</condition>
  <condition>Caffeine</condition>
  <condition>Polymorphism</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>in 2 administration (08:00 and 14:00) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleep deprivation</intervention_name>
    <description>40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).</description>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subject

        Exclusion Criteria:

          -  Treatment

          -  History of cardiovascular, psychiatric, pneumologic, haematologic, cancerology disease

          -  Nonvoluntary

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabien SAUVET, MD</last_name>
    <phone>0033 6 62 20 9331</phone>
    <email>fabien.sauvet@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mégane ERBLANG, MSC</last_name>
    <phone>0033 6 62 20 9331</phone>
    <email>megane.erblang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de recherche biomedical des armées</name>
      <address>
        <city>Brétigny-sur-Orge</city>
        <country>France</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Leger, Pr</last_name>
      <phone>00330112654543</phone>
      <email>damien.leger@aphp.com</email>
    </contact>
    <investigator>
      <last_name>Damien LEGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>May 18, 2019</last_update_submitted>
  <last_update_submitted_qc>May 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep deprivation</keyword>
  <keyword>cognition</keyword>
  <keyword>attention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

